Celgene (CELG), AstraZeneca (AZN) Initiative Durvalumab FUSION Program in Hematologic Disorders
Tweet Send to a Friend
Celgene Corporation (NASDAQ: CELG) and AstraZeneca (NYSE: AZN), announced the initiation of the FUSION clinical development program of durvalumab (MEDI4736) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
